Clinical trials: Phase I
Tuberculosis
Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB.
This study is designed to evaluate the safety of MVA85A in healthy volunteers in the UK who are latently infected with M.tb. A single vaccination with MVA85A, when administeredat a dose of 5 x 107pfu intradermally, is safe in…
- Trial name
- NCT00456183
- Testing
- MVA 85A
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Infection, Meningococcal
Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old
Phase I study to evaluate safety and immunogenicity in healthy adult subjects following a single dose administration of Meningococcal (Group A, C, W-135, and Y)-CRM197 Conjugate vaccine
- Trial name
- NCT04714229
- Testing
- Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine, Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Healthy
A Study To Taste Three New Types Of Crizotinib Formulation In Comparison Of An Oral Solution And To Measure The Amount Of Crizotinib In The Body After These Formulations Are Orally Given, Relative To Capsule Formulation
This study is intended to evaluate the sensory attributes and estimate the relative bioavailability of three prototype oral formulations.
- Trial name
- NCT02006277
- Testing
- Crizotinib prototype microsphere 0.529 mg/mg, crizotinib prototype microsphere 0.470 mg/mg, crizotinib prototype microsphere 0.420 mg/mg
- Where
- Belgium
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Pfizer
Major Depression Disorder, Depression
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls.
- Trial name
- DMT-Bolus (NCT06671977)
- Testing
- DMT-Medium Dose, DMT-Low Dose, THC-Medium Dose
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Deepak C. D'Souza
Drug-drug Interaction
A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects
To assess steady state pharmacokinetics (PK), safety and tolerability between AVP-786 (deuterated [d6] dextromethorphan hydrobromide [DM]/quinidine sulfate [Q]) and paroxetine and between AVP-786 and duloxetine.
- Trial name
- NCT02174822
- Testing
- AVP-786, Paroxetine, Duloxetine
- Where
- Australia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy
Relative Bioavailability of Single Doses of Dabigatran Etexilate When Administered Alone or in Combination With a Single Dose of Ketoconazole or in Combination With q.d. Ketoconazole at Steady State in Healthy Male and Female Volunteers
To investigate whether and to what extent the P-glycoprotein (P-gp) inhibitor ketoconazole affects plasma exposure of dabigatran.
- Trial name
- NCT02170675
- Testing
- Dabigatran etexilate, Ketoconazole
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Psoriasis Vulgaris
LEO 32731 - A Phase I Study in Healthy Subjects
LEO 32731 ("Study Drug") is an investigational drug which is being developed by LEO Pharma A/S ("the Sponsor") for treatment of psoriasis.
- Trial name
- NCT02514694
- Testing
- LEO32731
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Bioequivalence
Bioequivalence of Imeglimin Tablet Formulations
This is an open-label assessment of the bioequivalence of two 500 mg-tablet formulations of imeglimin (Tablet A [reference product] and Tablet B [test product]), in at least 16 healthy Caucasian volunteers.
- Trial name
- NCT03646331
- Testing
- Imeglimin Reference product, Imeglimin
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Poxel SA
Asthma
A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma
This study is a phase 1 single dose escalation study of SHR-1905 in healthy subjects and subjects with mild asthma. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of SHR-1905 in healthy…
- Trial name
- NCT04905602
- Where
- China
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Obesity
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide.
- Trial name
- NCT05671653
- Testing
- PF-07081532, Semaglutide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Enterotoxigenic E. Coli (ETEC) Infection
ACE527 Safety and Immunogenicity Study
The purpose of this study is to evaluate the safety and immune response to ACE527.
- Trial name
- NCT00901654
- Testing
- ACE527 vaccine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- TD Vaccines A/S
Healthy
PK and PD Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects
The hypothesis of this trial is that the test drug (Eritromax ®) pharmacokinetics and pharmacodynamics parameters are similar to the comparator drug (Eprex ®) in healthy subjects following administration of single intravenous…
- Trial name
- NCT01664195
- Testing
- Epoetin Alfa
- Where
- Brazil
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Bioequivalence
Bioequivalence (BE) Study Comparing Fluconazole 150mg Capsule Manufactured in China and in France
China Food and Drug Administration (CFDA) initiated a generic consistency evaluation program to evaluate the quality and efficacy of the products manufactured in China in 2016.
- Trial name
- NCT03621072
- Testing
- Fluconazole 150mg Capsule Originator, Fluconazole 150mg Capsule Localized Originator
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Subjects
Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects
Study is to investigate drug levels in the blood after taking single or multiple doses of the study drug, MT-7117, in healthy adults when taken together with another drug.
- Trial name
- NCT04793295
- Testing
- MT-7117
- Where
- 2 sites in United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma America, Inc.
Type2Diabetes
Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function
This study is a single-dose, parallel grouping, open-label phase I clinical study to evaluate the PK characteristics and safety of single subcutaneous injection of PB-119 in subjects with different degrees of renal insufficiency…
- Trial name
- NCT05328843
- Testing
- PB119
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- PegBio Co., Ltd.
Healthy Volunteer
A Study of DISC-3405 in Healthy Volunteers
This phase 1 study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of DISC-3405 in adult male and female healthy volunteers.
- Trial name
- NCT06050915
- Testing
- DISC-3405
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Disc Medicine, Inc
Healthy Volunteers
A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China
The objective of this study to assess the pharmacokinetics, safety, tolerability and immunogenicity following a single subcutaneous (SC) or intravenous (IV) dose of risankizumab in healthy Chinese participants.
- Trial name
- NCT05268068
- Testing
- Risankizumab
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AbbVie
Hepatic Impairment
A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects
The main purpose of this study is to evaluate the effect of varying degrees of impaired hepatic function (by Child-Pugh classification) on the pharmacokinetics (PK) of ABL001 after a single oral dose.
- Trial name
- NCT02857868
- Testing
- ABL001
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy
A Study of LY3526318 in Healthy Male Japanese Participants
This is a study of LY3526318 in healthy male Japanese. The main purposes of this study are to: Assess how safe and well tolerated LY3526318 is when given by mouth. Measure how LY3526318 affects the kidney and the liver.
- Trial name
- NCT05580250
- Testing
- LY3526318, Iohexol, Simvastatin
- Where
- Japan
- Volunteers
- healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
COVID-19, Coronavirus Pneumonia
A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects
This study is divided into two parts, including Part I: a randomized, open-label, positive drug-controlled, single ascending dose (SAD) study, a food effect (FE) study, and Part II: a randomized, double-blind, placebo-controlled…
- Trial name
- NCT06860282
- Testing
- Remdesivir, CX2101A
- Where
- China
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Heronova Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.